[Granulosa cell tumor of the ovary; evaluation of therapeutic results].
In 1956-1985 in the Oncological Research Institute in Brno a total of 70 patients was treated on account of granulosa-cell tumours of the ovary. This accounts for 10% of all ovarian malignities treated in the Institute during this period. The initial treatment of all patients was surgery, i.e. abdominal hysterectomy with bilateral adnexectomy, performed in 54.5% of the patients, uni- or bilateral adnexectomy in 35.7%, supravaginal amputation of the uterus with adnexectomy in 7.1% and in 2.7% (two patients) exploratory laparotomy only. All patients had irradiation of the pelvic area, in recent years the area of external irradiation was extended with regard to the lymphographic finding. This examination has become an integral part of the pre-treatment routine examination of every single patient. Comprehensive treatment of the tumour comprised chemotherapy involving in a major number of patients an adjuvant chemotherapeutical regime of CVF (Cyclophosphamide, Vinblastin, Ftorouracil), later a MAFC regime (Methotrexate, Actinomycin D, Cyclohosphamide, Ftorouracil). In more advanced tumours or mixed tumours according to histopathological analysis, in recent years a chemotherapeutic regime of CAP is used (Cyclophosphamide, platinum, Adriblastina) or VAB (Vinblastin, Adriblastina, Bleomycin), or a combination of platinum, Vinblastin and Bleomycin. In the submitted group a recovery extending over five years has been recorded in 63.6%, 60.5% of the patients survive 10 years and 54.1% of the women 15 years. In stage I 5-year survival is 82.5%, in stage Ia 85.3%.
Ptácková
B
B
Kucera
F
F
Kopecný
J
J
D000293:Adolescent; D000328:Adult; D000368:Aged; D002648:Child; D003131:Combined Modality Therapy; D005260:Female; D006106:Granulosa Cell Tumor / Q000401:mortality / Q000628:therapy*; D006801:Humans; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000401:mortality / Q000628:therapy*
Granulózo-celulární tumory ovaria, zhodnocení lécebných výsledků.